Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

Lexeo Therapeutics, Inc. Common Stock

Based in New York City, Lexeo Therapeutics is a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated.  Building on groundbreaking research from Weill Cornell Medicine and the University of California San Diego, Lexeo partners with preeminent institutions on the cutting edge of gene therapy research.  Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4 associated Alzheimer's disease programs, and is led by pioneers and experts with decades of collective experience in genetic medicines, rare disease drug development, manufacturing and commercialization. 

For more information, please visit www.lexeotx.com.

Sarepta Therapeutics

Woodline Partners

Alexandria Venture Investments

Omega Funds

PBM Capital Group

Invus

Alzheimer's Drug Discovery Foundation

Janus Henderson Investors

Longitude Capital

Lundbeckfonden Ventures

CAM Capital

Verition Fund Management

D1 Capital Partners

Eventide

Gray’s Creek Capital Partners

Intus Capital

Laurion Capital Management

Lexeo Therapeutics

Happy holidays to the team members, friends, family, partners, physicians and patients who have contributed to Lexeo’s work in 2023!

In 2023, Lexeo participated in numerous local events to join forces with patient advocates who are raising awareness about devastating diseases such as #Alzheimer’s, #FriedreichsAtaxia and #ArrhythmogenicCardiomyopathy.
 
Look back on some of our favorite photos from the year with Friedreich's Ataxia Research Alliance (FARA) and Alzheimer's Association®!

We are pleased to announce the FDA has granted Orphan Drug designation and Fast Track designation to LX2020, our #genetherapy candidate designed to treat arrhythmogenic cardiomyopathy caused by mutations in the PKP2 gene (PKP2-ACM).

Read the full press release here: https://lnkd.in/eq6wzhin

$LXEO shares began trading on Nasdaq last month.
 
Here's a peek behind the curtain of the biggest highlights from IPO day, ringing the Nasdaq closing bell and our event celebrating the Lexeo team for making this possible!
 
#LexeoListed

Yesterday, we reported our Q3 financial results and operational highlights. Check out the highlights below or read the full press release here: https://bit.ly/3Njy60f

	Dec '20	Dec '21	Dec '22	Dec '23
account payables	44.32K -	3.06M 6,806.74%	2.68M 12.51%	3.79M 41.67%
accumulated other comprehensive income loss
cash and cash equivalents	29.37M -	135.86M 362.53%	77.33M 43.08%	121.47M 57.06%
cash and short term investments	29.37M -	135.86M 362.53%	77.33M 43.08%	121.47M 57.06%
common stock	1.60K -	2K 24.69%	2K 0%	3K 50%
deferred revenue	140.38K -	46K 67.23%	8.60M 18,589.13%	10.67M 24.12%
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory
long term debt			10.65M -	9.03M 15.17%
long term investments
net debt	-29.37M -	-135.86M 362.53%	-63.85M 53.00%	-109.83M 72.00%
net receivables
other assets
other current assets		696K -	371K 46.70%	3K 99.19%
other current liabilities	513.02K -	4.34M 746.36%	8.84M 103.52%	169K 98.09%
other liabilities
other non current assets	2.50K -	2K 20%	3.25M 162,550%	3.25M 0.03%
other non current liabilities			185.03M -
othertotal stockholders equity	9.79K -	565K 5,668.84%	2.49M 340.71%	295.37M 11,762.33%
preferred stock
property plant equipment net		174K -	13.78M 7,816.67%	12.26M 10.99%
retained earnings	-5.55M -	-56.17M 912.45%	-115.45M 105.53%	-181.84M 57.51%
short term debt	513.02K -	4.31M 740.51%	2.83M 34.28%	2.60M 8.08%
short term investments
tax assets
tax payables	38.30K -	528K 1,278.45%	506K 4.17%	157K 68.97%
total assets	29.41M -	136.86M 365.36%	97.08M 29.07%	139.81M 44.02%
total current assets	29.41M -	136.68M 364.80%	80.05M 41.44%	124.29M 55.27%
total current liabilities	697.72K -	7.45M 967.62%	14.35M 92.63%	17.24M 20.14%
total debt			13.48M -	11.64M 13.68%
total investments
total liabilities	34.95M -	192.46M 450.75%	210.03M 9.13%	26.27M 87.49%
total liabilities and stockholders equity	29.41M -	136.86M 365.36%	97.08M 29.07%	139.81M 44.02%
total non current assets	2.50K -	176K 6,940.00%	17.03M 9,575%	15.51M 8.90%
total non current liabilities	34.25M -	185.01M 440.22%	195.68M 5.77%	9.03M 95.38%
total stockholders equity	-5.54M -	-55.60M 904.29%	-112.95M 103.15%	113.53M 200.51%

LXEO

COM:LEXEOTX

Lexeo

Last Close

7.89

08/11 21:00

Market Cap

541.62M

Beta: -

Volume Today

89.00K

Avg: -

Preview